Dr. Suresh Satpati is a Research Scientist at MD Anderson Cancer Center, where he focuses on cancer immunology, epigenomics, and computational biology. With a multidisciplinary background in bioinformatics, molecular modeling, and systems biology, his research spans cancer epigenetics, drug discovery, and stress physiology. He has co-authored over a dozen peer-reviewed publications in high-impact journals including BMC Genomics, Biochemical Journal, and Cancer Research. Dr. Satpati’s work has contributed to the identification of novel drug targets and inhibitors, such as LipY and DNA gyrase B in tuberculosis, and has elucidated the molecular effects of anticancer compounds like doxorubicin on bacterial and cancer cells. His recent focus on enhancer elements in cancer immunotherapy positions him at the frontier of personalized oncology. In addition to his cancer-focused research, Dr. Satpati has contributed to environmental and agricultural genomics, including the use of transcription factor analysis and recombinant bio-systems for bioremediation and stress tolerance. He is a strong advocate for interdisciplinary research, with ongoing interests in applying artificial intelligence and multi-omics data integration to biological discovery.